Period:
Draw Mode:
| Volume | 338,483 |
|
|||||
| News | - | ||||||
| Day High | 50.44 | Low High |
|||||
| Day Low | 48.89 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 1.08 | 2.2% | 50.23 | 19:59:35 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 49.36 | 48.89 | 50.44 | 50.23 | 49.15 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,344 | 338,483 | $ 49.63 | $ 16,797,898 | - | 30.665 - 54.86 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:58 | priorref | 182 | $ 50.23 | USD |
Sage Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.00B | 59.76M | 51.28M | $ 3.29M | $ -1.47M | -2.46 | -2,044.67 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 11.22k | 0.30% |
Sage Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 52.99 | 54.50 | 48.89 | 51.74 | 409,392 | -2.76 | -5.21% |
| 1 Month | 47.31 | 54.86 | 44.64 | 50.24 | 565,853 | 2.92 | 6.17% |
| 3 Months | 42.33 | 54.86 | 38.665 | 45.86 | 530,968 | 7.90 | 18.66% |
| 6 Months | 37.53 | 54.86 | 36.91 | 43.90 | 516,213 | 12.70 | 33.84% |
| 1 Year | 31.85 | 54.86 | 30.665 | 39.87 | 559,045 | 18.38 | 57.71% |
| 3 Years | 41.02 | 98.385 | 27.36 | 49.72 | 616,593 | 9.21 | 22.45% |
| 5 Years | 153.08 | 193.56 | 25.01 | 71.08 | 637,142 | -102.85 | -67.19% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |